TESARO price target lowered to $43 from $57 at RW Baird Baird lowered its price target on TESARO citing the potential for a significant new competitor for one of its key drugs. The firm believes its Rolapitant P3 commercial thesis remains intact but worry the its competitor's formulation may be closer to reality than previously thought. Shares remain Outperform rated but cautious.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
TESARO submits rolapitant NDA to FDA TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.